News >

FDA Approves Frontline Atezolizumab for PD-L1–High NSCLC

Jason M. Broderick @jasoncology
Published: Monday, May 18, 2020

The FDA has approved single-agent atezolizumab (Tecentriq) as a first-line treatment for adult patients with metastatic non–small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression, as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.

Regarding safety, TRAEs occurred in 60.5% (arm A) and 85.2% (arm B) of patients.
FDA Approves Genentech’s Tecentriq as a First-Line Monotherapy for Certain People With Metastatic Non-Small Cell Lung Cancer. Published May 18, 2020. https://bit.ly/3fYAw29. Accessed May 18, 2020.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x